Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - topotecanum - lyophilisat - préparation à sec: topotecanum 4 mg pour topotecani hydrochloridum, l'acide tartaricum, mannitolum, pour le verre. - de l'ovaire, cancer du poumon, du col de l'utérus - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - topotecanum - lyophilisat - préparation à sec: topotecanum 1 mg à topotecani hydrochloridum, l'acide tartaricum, mannitolum, pour le verre. - de l'ovaire, cancer du poumon, du col de l'utérus - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - topotecanum - capsules - topotecanum 0.25 mg ut topotecani hydrochloridum, oleum vegetabile hydrogenatum, glyceroli monostearas 40-55, kapselhülle: gelatina, e 171, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum) pro capsula. - les soins palliatifs à récidivant kleinzelligem du poumon avec extensive disease, si une nouvelle i. v. chimiothérapie n'est pas affiché. - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - topotecanum - capsules - topotecanum 1 mg ut topotecani hydrochloridum, oleum vegetabile hydrogenatum, glyceroli monostearas 40-55, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum) pro capsula. - les soins palliatifs à récidivant kleinzelligem du poumon avec extensive disease, si une nouvelle i. v. chimiothérapie n'est pas affiché. - synthetika

Canada - français - Health Canada

novartis pharmaceuticals canada inc - topotécane (chlorhydrate de topotécan) - poudre pour solution - 4mg - topotécane (chlorhydrate de topotécan) 4mg - antineoplastic agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - topotecanum - lyophilisat - praeparatio sicca: topotecanum 4 mg ut topotecani hydrochloridum, acidum tartaricum, mannitolum, acidum hydrochloridum aut natrii hydroxidum, pro vitro corresp. natrium 1.68 mg. - de l'ovaire, cancer du poumon, du col de l'utérus - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - topotecanum - lyophilisat - praeparatio sicca: topotecanum 1 mg ut topotecani hydrochloridum, acidum tartaricum, mannitolum, acidum hydrochloridum aut natrii hydroxidum, pro vitro corresp. natrium 0.46 mg. - de l'ovaire, cancer du poumon, du col de l'utérus - synthetika

Union européenne - français - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agents antinéoplasiques - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. pour plus d'informations sur le statut du récepteur du facteur de croissance épidermique humain 2 (her2), veuillez vous référer à la section 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. pour plus d'informations sur le statut her2, veuillez vous référer à la section 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

basilea pharmaceutica international ag, allschwil - isavuconazonium - poudre pour solution à diluer pour perfusion - préparation à sec: isavuconazonium 200 mg à isavuconazonii sulfamidés, mannitolum, pour le verre. - antimykotikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - tedizolidi phosphas - poudre pour solution à diluer pour perfusion - tedizolidi phosphas 200 mg, mannitolum, natrii hydroxidum, l'acide hydrochloridum, pour le verre. - les maladies infectieuses - synthetika